Brief: Cytrx presents positive interim results from on-going clinical trial

LadRx

11/11/2016 14:00

Nov 11 (Reuters) - Cytrx Corp  CYTR.O  
    * Cytrx says dose-limiting toxicities were not observed in 
either cohort, and no clinically significant cardiac toxicities 
were seen 
    * Cytrx says there were nine treatment-related serious 
adverse events, and no treatment-related deaths 
    * Cytrx presents positive interim results from on-going 
phase 1b/2 aldoxorubicin combination clinical trial at the 2016 
ctos annual meeting 
 
Source text for Eikon:  ID:nPn1xydR3a  
Further company coverage:  CYTR.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))